{"mainPropery":{"diseaseId":7674,"diseaseName":"Spinal muscular atrophy","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7674/spinal-muscular-atrophy","synonyms":["SMA"],"synonyms-with-source":[{"name":"SMA","source":"https://www.ncbi.nlm.nih.gov/books/NBK1352/"}],"identifiers":[{"identifierType":"UMLS","identifierId":"C0026847"}]},"diseaseCategories":[],"organizations":[{"resourceID":520,"resourceName":"Cure SMA","abbreviation":"","address1":"925 Busse Road","address2":"","address3":"","address4":"","address5":"","city":"Elk Grove","state":"IL","zip":"60007","country":"United States","phone":"847-367-7620","tty":"","tollFree":"800-886-1762","fax":"847-367-7623","email":"info@curesma.org","url":"http://www.curesma.org","freeText":""},{"resourceID":521,"resourceName":"Spinal Muscular Atrophy Foundation","abbreviation":"","address1":"888 Seventh Avenue","address2":"Suite 400","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10019","country":"United States","phone":"646-253-7100","tty":"","tollFree":"877-FUND-SMA (877-386-3762) ","fax":"212-247-3079","email":"info@smafoundation.org","url":"http://www.smafoundation.org","freeText":""},{"resourceID":935,"resourceName":"Muscular Dystrophy Association","abbreviation":"MDA","address1":"222 S Riverside Plaza","address2":"Suite 1500","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60606","country":"United States","phone":"","tty":"","tollFree":"1-833-275-6321 (Helpline)","fax":"","email":"resourcecenter@mdausa.org","url":"https://www.mda.org","freeText":""},{"resourceID":3532,"resourceName":"SMA Gruba","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Turkey","phone":"0535 715 3781","tty":"","tollFree":"","fax":"","email":"smagruba-iletisim@hotmail.com","url":"http://smagrubu.net/","freeText":""},{"resourceID":3533,"resourceName":"SMA Europe","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"Europe","state":"","zip":"","country":"","phone":"+44 (0)1789 801159","tty":"","tollFree":"","fax":"","email":"vanessa@sma-europe.eu","url":"http://www.sma-europe.eu/","freeText":""},{"resourceID":3929,"resourceName":"Spinal Muscular Atrophy Association of Australia Inc.","abbreviation":"SMA Australia","address1":"PO Box 5245 (mail)","address2":"Unit 7 16-28 Melverton Drive  (office)","address3":"","address4":"","address5":"","city":"Hallam Vic","state":"","zip":"3803","country":"Australia","phone":"(03) 9796 5744","tty":"","tollFree":"","fax":"03 83737 7787","email":"smaaa@smaaustralia.org.au","url":"http://smaaustralia.org.au/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Spinal%20muscular%20atrophy%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Spinal muscular atrophy. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Spinal+muscular+atrophy%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Spinal muscular atrophy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=spinalmuscularatrophy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Spinal muscular atrophy. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1135/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000996.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Spinal-Muscular-Atrophy-Fact-Sheet' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1181436-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=sma' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/reporter.cfm' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1549,"resourceId":2177,"resourceName":"National Human Genome Research Institute","descriptionText":"The <a href='http://www.genome.gov/20519681' target='_blank'>National Human Genome Research Institute's</a> (NHGRI) website has an information page on this topic. NHGRI is part of the National Institutes of Health and supports research on the structure and function of the human genome and its role in health and disease.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:253400' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2762,"resourceId":520,"resourceName":"Cure SMA","descriptionText":"<a href='http://events.curesma.org/site/PageNavigator/SmartMoves/SMArtMoves.html' target='_blank'>SMArt Moves</a>,&nbsp;a disease awareness and educational campaign launched by&nbsp;<a href='http://www.curesma.org/' target='_blank'>Cure SMA</a>, provides resources for&nbsp;parents, pediatricians and other healthcare professionals to promptly recognize and diagnose the early signs of spinal muscular atrophy (SMA). SMArt Moves&nbsp;has an <a href='http://www.curesma.org/documents/research-documents/smart-moves-toolkit.pdf' target='_blank'>SMA Diagnostic Toolkit</a> to help healthcare professionals recognize SMA in their patients.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2763,"resourceId":520,"resourceName":"Cure SMA","descriptionText":"<a href='http://www.curesma.org/sma/about-sma/' target='_blank'>Cure SMA</a>, an organization dedicated to the treatment of SMA and providing families with support, provides information about the types, causes and diagnosis of SMA.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"}],"overviewQuestion":{"questionId":2659,"questionText":"What is spinal muscular atrophy?","answerText":"Spinal muscular atrophy (SMA) is a group of genetic neuromuscular disorders that affect the nerve cells that control voluntary muscles (motor neurons). The loss of motor neurons causes progressive muscle weakness and loss of movement due to muscle wasting (atrophy). The severity of the symptoms, the age at which symptoms,&nbsp; begin, and genetic cause varies by type. Many types of SMA mainly affect the muscles involved in walking, sitting, arm movement, and head control. Breathing and swallowing may also become difficult as the disease progresses in many types of SMA. In some types of SMA, the loss of motor neurons makes it hard to control movement of the hands and feet.[2299][2300][2302] <br />\r\n<br />\r\nSMA type 1, 2, 3, and 4 are caused by changes (pathogenic variants, also know as mutations) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/SMN1\" tabindex=\"-1\" target=\"_blank\">SMN1</a></em> gene and are inherited in an autosomal recessive manner. Extra copies of the nearby related gene, <em><a href=\"http://ghr.nlm.nih.gov/gene/SMN2\" tabindex=\"-1\" target=\"_blank\">SMN2</a>,</em> modify the severity of SMA. There are other rarer types of SMA caused by changes in different genes. Other autosomal recessive forms include&nbsp;<a href=\"https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy-with-progressive-myoclonic-epilepsy\" target=\"_blank\">SMA with progressive myoclonic epilepsy</a> (SMA-PME) caused by changes in the&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/ASAH1\" target=\"_blank\">ASAH1</a></em> gene and <a href=\"https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy-with-respiratory-distress-type-1\" target=\"_blank\">SMA with respiratory distress 1</a> (SMARD1) caused by changes in the <em><a href=\"https://ghr.nlm.nih.gov/gene/IGHMBP2\" target=\"_blank\">IGHMBP2</a></em> gene. Autosomal dominant forms include <a href=\"https://ghr.nlm.nih.gov/condition/distal-hereditary-motor-neuropathy-type-v\" target=\"_blank\">distal MSA type V</a> &nbsp;(DSMA-V) caused by changes in&nbsp;<a href=\"https://ghr.nlm.nih.gov/gene/BSCL2\" target=\"_blank\"><em>BSCL2</em></a> and <em><a href=\"https://ghr.nlm.nih.gov/gene/GARS\" target=\"_blank\">GARS</a></em>, <a href=\"https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy-with-lower-extremity-predominance\" target=\"_blank\">SMA with lower extremity predominance</a> (SMA-LED) caused by changes in  <em><a href=\"http://ghr.nlm.nih.gov/gene/DYNC1H1\" tabindex=\"-1\" target=\"_blank\">DYNC1H1</a> or </em><em><a href=\"https://ghr.nlm.nih.gov/gene/BICD2\" target=\"_blank\">BICD2</a></em>, and adult-onset form of SMA caused changes by <em><a href=\"http://ghr.nlm.nih.gov/gene/VAPB\" tabindex=\"-1\" target=\"_blank\">VAPB</a></em>.&nbsp;<a href=\"http://www.genome.gov/Glossary/index.cfm?id=209\" tabindex=\"-1\" target=\"_blank\"> X-linked</a> forms include <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1333/\" target=\"_blank\">X-linked infantile SMA</a> caused by changes in <em><a href=\"http://ghr.nlm.nih.gov/gene/UBA1\" tabindex=\"-1\" target=\"_blank\">UBA1</a></em>.[2301] <br />\r\n<br />\r\nDiagnosis of SMA is suspected by symptoms and confirmed by genetic testing. Treatments are in general supportive aiming to increase quality of life and avoid complications. Treatments may include physical therapy, nutrition support, <a href=\"https://www.merckmanuals.com/home/lung-and-airway-disorders/rehabilitation-for-lung-and-airway-disorders/chest-physical-therapy\" target=\"_blank\">chest physiotherapy</a>, and, in severe cases, breathing machines (<a href=\"https://medlineplus.gov/ency/patientinstructions/000458.htm\" target=\"_blank\">ventilators</a>).[14883][14884] In December 2016, <a href=\"https://medlineplus.gov/druginfo/meds/a617010.html\" target=\"_blank\">nusinersen</a> (Spinraza) became the first FDA approved treatment for SMA types 1, 2, 3, and 4. Continued treatment with nusinersen has been shown to slow the progression of the disease and even improve muscle function, but individual response to the treatment does vary.[14885][14886] &nbsp;Due to the success of nusinersen as well as other promising treatments presently in clinical trials,&nbsp;<span style=\"font-family: Roboto, Verdana, Geneva, Tahoma, sans-serif; color: #333333;\">SMA caused by changes in the&nbsp;<em>SMN1</em>&nbsp;gene has been added to the list of recommended newborn screening</span><span style=\"font-family: Roboto, Verdana, Geneva, Tahoma, sans-serif; color: #333333;\">&nbsp;tests in the United States, so that  treatment may begin before symptoms develop. However, <span style=\"font-family: Roboto, Verdana, Geneva, Tahoma, sans-serif; color: #333333;\">as of July 2018,&nbsp;</span>not all States have added the test to their newborn screening panel.[14910]</span>","dateModified":"2018-08-25T00:00:00"},"basicQuestions":[{"questionId":3333,"questionText":"What are the signs and symptoms of spinal muscular atrophy?","answerText":"Spinal muscular atrophy (SMA) is primarily characterized by progressive muscle weakness and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003188.htm\" tabindex=\"-1\" target=\"_blank\">atrophy</a>. Depending on the type, onset may range from before birth to adolescence or young adulthood.[4685]<br />\r\n<br />\r\nSMA type 0 (the prenatal form) is the most severe form and begins before birth. Usually, the first symptom of type 0 is reduced movement of the fetus that is first seen between 30 and 36 weeks of the pregnancy. After birth, these newborns have little movement and have difficulties with swallowing and breathing.[2299] Life span is approximately 2-6 months.[4685]<br />\r\n<br />\r\nThere are 3 types of SMA that tend to affect children before the age of one (SMA type I, SMA type II, and X-linked SMA). <a href=\"https://rarediseases.info.nih.gov/gard/7883/spinal-muscular-atrophy-1/resources/1\" target=\"_blank\">SMA type 1</a>&nbsp;is a severe form that may be apparent at birth or the first few months of life. Features may include difficulty swallowing or breathing and inability to sit without support.[2301] The life span is usually less than 2 years.[4685]&nbsp;<a href=\"https://rarediseases.info.nih.gov/gard/4945/spinal-muscular-atrophy-type-2/resources/1\" target=\"_blank\">SMA type II</a>&nbsp;typically becomes apparent between 6 and 12 months of age; affected children may sit without support, although they cannot stand or walk unaided.[2301] About 70% of&nbsp;people with this type live to be at least 25 years of age.[4685] X-linked infantile SMA is similar to SMA type I; additional features may include joint deformities (contractures) or even broken bones at birth&nbsp;in very severe cases.[2301]<br />\r\n<br />\r\nThree other types of SMA can affect people in early childhood and adulthood.[2301] SMA type III (also called Kugelberg-Welander disease or juvenile type) is a milder form of spinal muscular atrophy with symptoms that generally appear between early childhood (older than age 1 year) and early adulthood. People with type III are able to stand and walk without help, although they usually lose this ability later in life.[2299] SMA type IV and Finkel type occur in adulthood, usually after age 30. Symptoms of adult-onset SMA are usually mild to moderate and include muscle weakness, tremor and twitching.[2299]","dateModified":"2016-01-07T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":2299,"authors":"","articleTitle":"Learning About Spinal Muscular Atrophy","bookWebsiteJournalTitle":"National Human Genome Research Institute","date":"February 19, 2012","volume":"","pages":"","url":"https://www.genome.gov/20519681/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":2301,"authors":"","articleTitle":"Spinal muscular atrophy","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"January 2013","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":4685,"authors":"Thomas W Prior, PhD, FACMG and Barry S Russman, MD","articleTitle":"Spinal Muscular Atrophy","bookWebsiteJournalTitle":"GeneReviews","date":"November 2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1352/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3336,"questionText":"How is spinal muscular atrophy inherited?","answerText":"Most forms of spinal muscular atrophy (types I, II, III, and IV, specifically) are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" tabindex=\"-1\" target=\"_blank\">autosomal recessive</a> pattern.[2301] This means that to be affected, a person must have a <a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" tabindex=\"-1\" target=\"_blank\">mutation</a> in both copies of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" tabindex=\"-1\" target=\"_blank\">gene</a> in each cell. The parents of an affected person usually each carry one mutated copy of the gene and are referred to as carriers. Carriers typically do not show signs or symptoms of the condition. When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) risk to have the condition, a 50% (1 in 2) risk to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.<br />\r\n<br />\r\nFinkel type spinal muscular atrophy is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" tabindex=\"-1\" target=\"_blank\">autosomal dominant</a> pattern, which means an affected person only needs a mutation in one copy of the responsible gene in each cell.[2301]<br />\r\n<br />\r\nX-linked infantile spinal muscular atrophy is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002051.htm\" tabindex=\"-1\" target=\"_blank\">X-linked</a> pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation would have to occur in both copies of the gene to cause the disorder. Because it is unlikely that females will have two altered copies of this gene, males are affected by X-linked disorders much more frequently than females. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.[2301]","dateModified":"2016-01-07T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":2301,"authors":"","articleTitle":"Spinal muscular atrophy","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"January 2013","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/spinal-muscular-atrophy","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3337,"questionText":"How might spinal muscular atrophy be treated?","answerText":"Treatment for SMA may vary depending on the subtype of SMA and severity of symptoms, but generally focuses on supportive care to increase the person's quality of life. In general, treatment may include physical therapy and assistive equipment to increase mobility, such as leg braces, walkers, and wheelchairs. Back braces may be used to assist sitting and prevent <a href=\"https://medlineplus.gov/scoliosis.html\" target=\"_blank\">scoliosis</a> and other complications affecting the backbone. Special breathing exercises, <a href=\"https://www.aboutkidshealth.ca/Article?contentid=2447&amp;language=English\" target=\"_blank\">cough machines</a>, and <a href=\"https://www.merckmanuals.com/home/lung-and-airway-disorders/rehabilitation-for-lung-and-airway-disorders/chest-physical-therapy\" target=\"_blank\">chest physiotherapy</a> can help maintain the function of the lungs and keep the airways clear of mucous, especially in times of illness. A dietitian may help support nutrition if eating or swallowing becomes difficult.[14883][14884]&nbsp;<br />\r\n<ul>\r\n</ul>\r\nFor SMA types 1, 2, 3, and 4, <a href=\"https://medlineplus.gov/druginfo/meds/a617010.html\" target=\"_blank\">nusinersen</a> (Spinraza) is the first and only FDA approved treatment. Continued treatment with nusinersen has been found to increase motor function and slow the progression of symptoms. Many babies and young children with types 1 and 2 are able to reach developmental milestones and maintain those milestones over time. In general, breathing problems, nutrition problems, and hospital admissions also decrease. Older children with type 3 and adults with type 4 have also been shown to benefit from continuous treatment with nusinersen, including, for some, regaining the ability to walk longer distances, improving arm movement, and slowing or stopping the progression of the disorder. Ongoing, long term medical studies continue to report improvements. However, response to treatment does vary and some people with SMA types 1, 2, 3, or 4 may not respond to the drug at all or may have medical complications that prevent use of the treatment.[14885][14886]<br />\r\n<br />\r\nCure SMA has more detailed information about the management of medical issues associated with SMA. Their webpage includes hyperlinks to the latest published consensus medical guidelines (2018) for SMA treatment to share with the doctors involved in the care of the person with SMA.<br />\r\n<ul>\r\n    <li>CureSMA:&nbsp;<a href=\"http://www.curesma.org/support-care/living-with-SMA/medical-issues/\" target=\"_blank\">Living with SMA Medical Issues</a></li>\r\n</ul>","dateModified":"2018-08-25T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":14883,"authors":"Mercuri E, Finkel RS, Muntoni F, et al","articleTitle":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","bookWebsiteJournalTitle":"Neuromuscul Disord","date":"February 2018","volume":"28(2)","pages":"103-115","url":"https://www.sciencedirect.com/science/article/pii/S0960896617312841?via%3Dihub","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14884,"authors":"Finkel RS, Mercuri E, Meyer OH, et al","articleTitle":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","bookWebsiteJournalTitle":"Neuromuscul Disord","date":"March 2018","volume":"28(3)","pages":"197-207","url":"https://www.sciencedirect.com/science/article/pii/S0960896617312907?via%3Dihub","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14885,"authors":"Kariyawasam D, Carey KA, Jones KJ, Farrar MA","articleTitle":"New and developing therapies in spinal muscular atrophy","bookWebsiteJournalTitle":"Paediatr Respir Rev","date":"April 5, 2018","volume":"pii: S1526-0542(18)","pages":"30048-4","url":"https://www.ncbi.nlm.nih.gov/pubmed/29703692","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":14886,"authors":"Claborn MK, Stevens DL, Walker CK, Gildon BL","articleTitle":"Nusinersen: A Treatment for Spinal Muscular Atrophy","bookWebsiteJournalTitle":"Ann Pharmacother","date":"July 1, 2018","volume":"","pages":"1060028018789956","url":"https://www.ncbi.nlm.nih.gov/pubmed/30008228","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":7883,"relatedDiseaseName":"Spinal muscular atrophy 1","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":9646,"relatedDiseaseName":"Spinal muscular atrophy Ryukyuan type","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":4947,"relatedDiseaseName":"Spinal muscular atrophy type 1 with congenital bone fractures","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":4945,"relatedDiseaseName":"Spinal muscular atrophy type 2","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":198,"relatedDiseaseName":"Spinal muscular atrophy type 3","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":564,"relatedDiseaseName":"Spinal muscular atrophy type 4","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":8592,"relatedDiseaseName":"Spinal muscular atrophy with respiratory distress 1","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":58512,"abbreviatedInquiry":"If members of a couple are carriers of SMA and had a baby affected with SMA type 1, is there a chance that they could have babies affected with other types of SMA or it will always be the same type that would appear in their children?","caseQuestions":[{"questionId":11123,"questionText":"If members of a couple are carriers of SMA and had a baby affected with SMA type 1, is there a chance that they could have babies affected with other types of SMA or it will always be the same type that would appear in their children?","answerText":"If a couple has already had a child with SMA, while it is more likely that another affected sibling would have the same type, it is not definite.[12297] There are rare families reported in which marked differences in severity have been present in affected siblings with the same&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/SMN2\" target=\"_blank\">SMN2</a></em>&nbsp;copy number.[12302][8553]<br />\r\n<br />\r\nThe genetics of SMA is complex, and distinction between subtypes of childhood-onset, autosomal recessive SMA is based on the age of onset, achieved milestones, and lifespan.[12302]&nbsp;While genetic testing of a fetus at risk can confirm a diagnosis of SMA, it cannot distinguish between the 3 types&nbsp;of childhood onset SMA (types I, II and III).[12297] Because of this, if a fetus is at risk or is diagnosed with SMA, the potential severity and prognosis cannot be predicted.[12295]&nbsp;For example, if 3 copies of the&nbsp;<em>SMN2</em>&nbsp;gene are detected in a fetus,  type I, II or III can result. Similarly, the presence of 2 copies is typical for type I, but could also result in type II. On the other hand, having a single copy of <em>SMN2</em> is rare but is highly predictive of severe type I with a very poor prognosis.[12295]<br />\r\n<br />\r\n<strong>Couples who have had a child with SMA are strongly encouraged to meet with a genetic counselor or other genetics professional.</strong> A genetics professional can&nbsp;<span style=\"font-size: 12pt;\">evaluate personal genetic circumstances, assess&nbsp;</span>recurrence risks, and address questions and concerns. He/she can also discuss testing and management options in current or future pregnancies. For example, there are often options for couples who want to avoid having another affected child, or who want to find out early in pregnancy whether a fetus is affected.<br />\r\n<br />\r\nYou can visit SMA Support UK's website for&nbsp;<a href=\"http://www.smasupportuk.org.uk/the-genetics-of-sma\" target=\"_blank\">information about the genetics of SMA types I, II, and III</a>, and <a href=\"http://www.smasupportuk.org.uk/future-options-in-pregnancy\" target=\"_blank\">information about&nbsp;future options in pregnancy</a>.","dateModified":"2016-10-03T00:00:00","references":[{"referenceId":8553,"authors":"Thomas W Prior, PhD, FACMG and Barry S Russman, MD","articleTitle":"Spinal Muscular Atrophy","bookWebsiteJournalTitle":"GeneReviews","date":"November 2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1352/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12295,"authors":"D'Amico A, Mercuri E, Tiziano FD, Bertini E","articleTitle":"Spinal muscular atrophy","bookWebsiteJournalTitle":"Orphanet J Rare Dis","date":"November, 2011","volume":"6:71","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12297,"authors":"","articleTitle":"Future Options in Pregnancy","bookWebsiteJournalTitle":"Spinal Muscular Atrophy Support UK","date":"August, 2016","volume":"","pages":"","url":"http://www.smasupportuk.org.uk/future-options-in-pregnancy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12302,"authors":"Cusc√≥ I, et al","articleTitle":"SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings","bookWebsiteJournalTitle":"J Neurol","date":"January, 2006","volume":"253(1)","pages":"21-25","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2567,"questionText":"How can I find a genetics professional in my area?","answerText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by  the <a href=\"https://www.acmg.net/ACMG/Find_Genetic_Services/ACMG/ISGweb/FindaGeneticService.aspx?hkey=720856ab-a827-42fb-a788-b618b15079f9\" target=\"_blank\">American College of Medical Genetics</a>&nbsp;and the&nbsp;<a href=\"https://www.findageneticcounselor.com/\" target=\"_blank\">National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also <a href=\"http://ghr.nlm.nih.gov/handbook/consult?show=all\" target=\"_blank\">learn more about genetic consultations</a> from Genetics Home Reference.","dateModified":"2017-12-06T00:00:00","references":[]}]},{"caseId":33081,"abbreviatedInquiry":"Are there any other diseases or&nbsp;conditions that have similar symptoms to SMA,&nbsp;or mimic the symptoms of SMA?","caseQuestions":[{"questionId":5683,"questionText":"What conditions are part of the differential diagnosis for&nbsp;people with symptoms of spinal muscular atrophy?","answerText":"The main&nbsp;features of spinal muscular atrophy (SMA)&nbsp;include progressive muscle weakness and poor muscle tone (hypotonia), which may be present&nbsp;in a variety of conditions. (For a more detailed explanation of the signs and symptoms of SMA <a href=\"http://rarediseases.info.nih.gov/GARD/QnASelected.aspx?diseaseID=7674#3333\" target=\"_blank\">click here</a>.)&nbsp; The following conditions are part of the differential diagnosis for people with symptoms of SMA because they share similar features:[8553][8563]&nbsp;\r\n<ul>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/5575/Prader_Labhart_Willi_syndrome.aspx\" target=\"_blank\">Prader-Willi syndrome</a> and other <a href=\"http://www.genome.gov/11508982#al-5\" target=\"_blank\">chromosome abnormalities</a>\r\n    </li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/5714/Pompe_disease.aspx\" target=\"_blank\">Pompe disease </a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/congenital_myasthenia/congenital_myasthenia.htm\" target=\"_blank\">Congenital myasthenia</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/myopathy_congenital/myopathy_congenital.htm\" target=\"_blank\">Congenital myopathies</a> (such as <a href=\"http://ghr.nlm.nih.gov/condition/nemaline-myopathy\" target=\"_blank\">nemaline myopathy</a>, <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/6014/Central_core_disease.aspx\" target=\"_blank\">central core disease</a>, and <a href=\"http://ghr.nlm.nih.gov/condition/centronuclear-myopathy\" target=\"_blank\">myotubular myopathy</a>)\r\n    </li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/10419/Myotonic_dystrophy.aspx\" target=\"_blank\">Myotonic dystrophy</a>\r\n    </li>\r\n    <li><a href=\"http://www.mda.org/disease/cmd.html\" target=\"_blank\">Congenital muscular dystrophy</a>\r\n    </li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/6291/Duchenne_muscular_dystrophy.aspx\" target=\"_blank\">Duchenne muscular dystrophy</a>\r\n    </li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/5900/Becker_muscular_dystrophy.aspx\" target=\"_blank\">Becker muscular dystrophy </a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/kennedys/kennedys.htm\" target=\"_blank\">Kennedy's disease</a>\r\n    </li>\r\n    <li><a href=\"http://rarediseases.info.nih.gov/GARD/Condition/5786/Amyotrophic_lateral_sclerosis.aspx\" target=\"_blank\">Amyotrophic lateral sclerosis</a>\r\n    </li>\r\n    <li><a href=\"http://ghr.nlm.nih.gov/condition/zellweger-spectrum\" target=\"_blank\">Zellweger syndrome spectrum</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm\" target=\"_blank\">Peripheral neuropathies</a>, including Guillain-Barr&eacute; syndrome\r\n    </li>\r\n    <li>Central nervous system abnormalities\r\n    </li>\r\n    <li>Trauma&nbsp;to the spinal cord</li>\r\n</ul>","dateModified":"2015-03-25T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":8553,"authors":"Thomas W Prior, PhD, FACMG and Barry S Russman, MD","articleTitle":"Spinal Muscular Atrophy","bookWebsiteJournalTitle":"GeneReviews","date":"November 2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1352/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8563,"authors":"","articleTitle":"Spinal Muscular Atrophy","bookWebsiteJournalTitle":"NORD","date":"2012","volume":"","pages":"","url":"https://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1135/viewAbstract","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":662,"dateCreated":"2019-07-30T10:35:00","publishDate":"2019-07-30T00:00:00","title":"FDA Approves Innovative Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy","description":"The U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease","lastModified":"2019-07-30T10:35:00","isFeatured":false},{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":769,"genericName":"Risdiplam","tradeName":"Evrysdi","tradeLink":"https://www.evrysdi.com/","manufacturer":"","sponsor":"Genentech","indication":"August 2020, risdiplam (Evrysdi) was approved for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/risdiplam","medlinePlusLink":""},{"productId":657,"genericName":"Nusinersen","tradeName":"Spinraza","tradeLink":"https://www.spinraza.com/","manufacturer":"","sponsor":"Biogen, Inc","indication":"December 2016, nusinersen (Spinraza) was approved for the treatment of spinal muscular atrophy in pediatric and adult patients.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/spinraza","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617010.html"},{"productId":770,"genericName":"Onasemnogene abeparvovec","tradeName":"Zolgensma","tradeLink":"https://www.zolgensma.com/","manufacturer":"","sponsor":"AveXis, Inc.","indication":"May 2019, onasemnogene abeparvovec  (Zolgensma) was approved for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.","drugInformationLink":"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68cd4f06-70e1-40d8-bedb-609ec0afa471","medlinePlusLink":""}],"EncodedName":"Spinal_muscular_atrophy"}